跳至主要内容
临床试验/NCT05560412
NCT05560412已完成不适用

Zein Nanoparticles for Glycemic Control

Clinica Universidad de Navarra, Universidad de Navarra2 个研究点 分布在 1 个国家目标入组 69 人开始时间: 2023年1月10日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
69
试验地点
2
主要终点
Change in Fructosamine

研究概览

简要总结

The use of zein nanoparticles as vehicles for drug delivery is under study, but of the effects observed in empty nanoparticles, in laboratory animals, the reduction of glucose levels was something worth studying. Thus, the present research on patients with prediabetes has been proposed. The objective is to assess the efficacy of zein nanoparticles on the glycemic control. For this purpose, a randomized, double blind crossover study has been designed.

Target sample size is 60.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

The products (experimental and Placebo), will be produced by an external producer, who will retain the codes. None of the researchers involved in the study development or analyses will know the association until the end of the study.

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Overweight or obesity (BMI between 25 and 40 kg/m2
  • Presence of prediabetes (fasting glycemia in blood between 100 and 126 mg/dL)
  • No weight variations considered relevant (+/- 5%) in the last 3 months
  • Metformin treatment is allowed, as far as dose is stable (at least 2 months with unvaried dose).
  • Good physical and psychological state.

排除标准

  • 未提供

研究组 & 干预措施

control

Placebo Comparator

Subjects will consume daily a powder dissolved in water with zein

干预措施: control (Dietary Supplement)

Zein nanocapsules

Experimental

Subjects will consume daily a powder dissolved in water with nanoencapsulated zein

干预措施: Zein nanocapsules (Dietary Supplement)

结局指标

主要结局

Change in Fructosamine

时间窗: 28 days

Change in the levels of Fructosamine From day 0 to day 28

Change in GLP-1 AUC

时间窗: Baseline, 15, 30, 45 and 60 minutes

Change in AUC of postprandial GLP-1 levels after OGTT

次要结局

  • Continuous glucose levels(28 days)
  • Fasting Plasma glucose(28 days)
  • Insulin Levels(28 days)

研究者

发起方
Clinica Universidad de Navarra, Universidad de Navarra
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验